Key result
Decongestion strategies with loop diuretics remain the primary focus of treatment for heart failure hospitalizations despite sparse high-quality randomized trial data.
Discusses the evolving landscape of decongestion strategies in heart failure, referencing the historical DOSE trial.
Hospitalization for heart failure, usually due to volume overload, is among the most common reasons for hospitalization worldwide, and decongestion with loop diuretics is the primary focus of treatment in most patients.1 Despite the ubiquity of this clinical scenario in daily practice, high-quality data from randomized trials evaluating effective treatment approaches are sparse.2 The Diuretic Optimization Strategies Evaluation (DOSE) trial, published more than 11 years ago, compared strategies regarding dose level (high- vs. low-intensity loop diuretics) and means of administration (bolus vs. continuous infusion) in patients hospitalized with heart failure and congestion.3 Despite its modest size, that trial represented an . . .
No takes yet. Share an insight, caveat, or question.
G. Michael Felker (2022) conducted an editorial in Heart failure. Loop diuretics was evaluated. Decongestion strategies with loop diuretics remain the primary focus of treatment for heart failure hospitalizations despite sparse high-quality randomized trial data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: